Biblio
Export 989 results:
Author Title Type [ Year] Filters: First Letter Of Keyword is H [Clear All Filters]
“Psychopharmacological Medication Use in Frontotemporal Dementia at the Time of Diagnosis: Comparison with Alzheimer's Disease.”, J Alzheimers Dis, vol. 95, no. 2, pp. 677-685, 2023.
, “Re-Addressing Dementia by Network Medicine and Mechanism-Based Molecular Endotypes.”, J Alzheimers Dis, vol. 96, no. 1, pp. 47-56, 2023.
, “Refining Risk for Alzheimer's Disease Among Heterozygous APOEɛ4 Carriers.”, J Alzheimers Dis, vol. 94, no. 2, pp. 483-489, 2023.
, “Refining Risk for Alzheimer's Disease Among Heterozygous APOEɛ4 Carriers.”, J Alzheimers Dis, vol. 94, no. 2, pp. 483-489, 2023.
, “Refining Risk for Alzheimer's Disease Among Heterozygous APOEɛ4 Carriers.”, J Alzheimers Dis, vol. 94, no. 2, pp. 483-489, 2023.
, “Resveratrol Mediated Regulation of Hippocampal Neuroregenerative Plasticity via SIRT1 Pathway in Synergy with Wnt Signaling: Neurotherapeutic Implications to Mitigate Memory Loss in Alzheimer's Disease.”, J Alzheimers Dis, vol. 94, no. s1, pp. S125-S140, 2023.
, “Resveratrol Mediated Regulation of Hippocampal Neuroregenerative Plasticity via SIRT1 Pathway in Synergy with Wnt Signaling: Neurotherapeutic Implications to Mitigate Memory Loss in Alzheimer's Disease.”, J Alzheimers Dis, vol. 94, no. s1, pp. S125-S140, 2023.
, “The Role of Interferon-α in Neurodegenerative Diseases: A Systematic Review.”, J Alzheimers Dis, vol. 94, no. s1, pp. S45-S66, 2023.
, “Safety, Feasibility, and Potential Clinical Efficacy of 40 Hz Invisible Spectral Flicker versus Placebo in Patients with Mild-to-Moderate Alzheimer's Disease: A Randomized, Placebo-Controlled, Double-Blinded, Pilot Study.”, J Alzheimers Dis, vol. 92, no. 2, pp. 653-665, 2023.
, “Serotonin Degeneration and Amyloid-β Deposition in Mild Cognitive Impairment: Relationship to Cognitive Deficits.”, J Alzheimers Dis, vol. 96, no. 1, pp. 215-227, 2023.
, “Soluble TREM2, Alzheimer's Disease Pathology, and Risk for Progression of Cerebral Small Vessel Disease: A Longitudinal Study.”, J Alzheimers Dis, vol. 92, no. 1, pp. 311-322, 2023.
, “Understanding the Involvement of microRNAs in Mitochondrial Dysfunction and Their Role as Potential Biomarkers and Therapeutic Targets in Parkinson's Disease.”, J Alzheimers Dis, vol. 94, no. s1, pp. S187-S202, 2023.
, “Unlocking Modifiable Risk Factors for Alzheimer's Disease: Does the Oral Microbiome Hold Some of the Keys?”, J Alzheimers Dis, vol. 92, no. 4, pp. 1111-1129, 2023.
, “Untangling the Role of TREM2 in Conjugation with Microglia in Neuronal Dysfunction: A Hypothesis on a Novel Pathway in the Pathophysiology of Alzheimer's Disease.”, J Alzheimers Dis, vol. 94, no. s1, pp. S319-S333, 2023.
, “Vacuolar Protein-Sorting Proteins Are Reduced Even Before Cognitive Decline in a Mouse Model of Alzheimer's Disease.”, J Alzheimers Dis, vol. 96, no. 3, pp. 1011-1017, 2023.
, “5-Hydroxymethylcytosine Signatures in Circulating Cell-Free DNA as Diagnostic Biomarkers for Late-Onset Alzheimer's Disease.”, J Alzheimers Dis, vol. 85, no. 2, pp. 573-585, 2022.
, “5-Hydroxymethylcytosine Signatures in Circulating Cell-Free DNA as Diagnostic Biomarkers for Late-Onset Alzheimer's Disease.”, J Alzheimers Dis, vol. 85, no. 2, pp. 573-585, 2022.
, “Alteration of Gut Microbiota in Alzheimer's Disease and Their Relation to the Cognitive Impairment.”, J Alzheimers Dis, vol. 88, no. 3, pp. 1103-1114, 2022.
, “Alzheimer's Disease: Key Insights from Two Decades of Clinical Trial Failures.”, J Alzheimers Dis, vol. 87, no. 1, pp. 83-100, 2022.
, “Analysis and Identification Genetic Effect of SARS-CoV-2 Infections to Alzheimer's Disease Patients by Integrated Bioinformatics.”, J Alzheimers Dis, vol. 85, no. 2, pp. 729-744, 2022.
, “Antihypertensive Medication Class and the Risk of Dementia and Cognitive Decline in Older Adults: A Secondary Analysis of the Prospective HELIAD Cohort.”, J Alzheimers Dis, vol. 89, no. 2, pp. 709-719, 2022.
, “Antihypertensive Medication Class and the Risk of Dementia and Cognitive Decline in Older Adults: A Secondary Analysis of the Prospective HELIAD Cohort.”, J Alzheimers Dis, vol. 89, no. 2, pp. 709-719, 2022.
, “Association Between Serum Vitamins and the Risk of Alzheimer's Disease in Chinese Population.”, J Alzheimers Dis, vol. 85, no. 2, pp. 829-836, 2022.
, “Association of Alzheimer's Disease with COVID-19 Susceptibility and Severe Complications: A Nationwide Cohort Study.”, J Alzheimers Dis, vol. 87, no. 2, pp. 701-710, 2022.
, “Association of Cholinergic Basal Forebrain Volume and Functional Connectivity with Markers of Inflammatory Response in the Alzheimer's Disease Spectrum.”, J Alzheimers Dis, vol. 85, no. 3, pp. 1267-1282, 2022.
,